40 results on '"Granato, Anna Maria"'
Search Results
2. Dendritic cell vaccines as cancer treatment: focus on 13 years of manufacturing and quality control experience in advanced therapy medicinal products
3. Skewing effect of sulprostone on dendritic cell maturation compared with dinoprostone
4. Metformin and insulin impact on clinical outcome in patients with advanced hepatocellular carcinoma receiving sorafenib: Validation study and biological rationale
5. Interplay Between SIRT-3, Metabolism and Its Tumor Suppressor Role in Hepatocellular Carcinoma
6. Stability Program in Dendritic Cell Vaccines: A “Real-World” Experience in the Immuno-Gene Therapy Factory of Romagna Cancer Center
7. Radiotherapy and High-Dose Interleukin-2: Clinical and Immunological Results of a Proof of Principle Study in Metastatic Melanoma and Renal Cell Carcinoma
8. Biofunctional characteristics of in situ and invasive breast carcinoma
9. Potency Assessment of Dendritic Cell Anticancer Vaccine: Validation of the Co-Flow DC Assay
10. Tumor endothelial marker 8 expression levels in dendritic cell-based cancer vaccines are related to clinical outcome
11. Urine Telomerase Activity for the Detection of Bladder Cancer in Females
12. Biomarker prediction of clinical outcome in operable breast cancer patients treated with tamoxifen
13. Prognostic significance of biologic markers in node-negative breast cancer patients: a prospective study
14. Dendritic Cell Vaccination in Metastatic Melanoma Turns “Non-T Cell Inflamed” Into “T-Cell Inflamed” Tumors
15. HER-2 Expression and Cell Proliferation: Prognostic Markers in Patients With Node-Negative Breast Cancer
16. Basic fibroblast growth factor and vascular endothelial growth factor serum levels in breast cancer patients and healthy women: useful as diagnostic tools?
17. Complementary vaccination protocol with dendritic cells pulsed with autologous tumour lysate in patients with resected stage III or IV melanoma: protocol for a phase II randomised trial (ACDC Adjuvant Trial)
18. Results from the first step of a phase II study of vaccination with autologous dendritic cells loaded with autologous tumour homogenate in glioblastoma.
19. Radiotherapy as an immunological booster in patients with metastatic melanoma or renal cell carcinoma treated with high-dose interleukin-2: Interim analysis data.
20. Vaccination with autologous dendritic cells loaded with autologous tumor lysate or homogenate combined with immunomodulating radiotherapy and/or preleukapheresis IFN-α in patients with metastatic melanoma: a randomised “proof-of-principle” phase II study
21. Effect of vaccination with autologous tumor-loaded dendritic cells on intratumoral regulatory T cells in metastatic melanoma patients.
22. Erratum to “Unexpected High Response Rate to Traditional Therapy after Dendritic Cell-Based Vaccine in Advanced Melanoma: Update of Clinical Outcome and Subgroup Analysis”
23. FRET microscopy autologous tumor lysate processing in mature dendritic cell vaccine therapy
24. Unexpected High Response Rate to Traditional Therapy after Dendritic Cell-Based Vaccine in Advanced Melanoma: Update of Clinical Outcome and Subgroup Analysis
25. Tumor endothelial marker 8 expression levels in dendritic cell-based cancer vaccines are related to clinical outcome
26. Iressa strengthens the cytotoxic effect of docetaxel in NSCLC models that harbor specific molecular characteristics
27. Do Serum Angiogenic Growth Factors Provide Additional Information to That of Conventional Markers in Monitoring the Course of Metastatic Breast Cancer?
28. Immunosuppression in Renal Cancer: Differential Expression of Signal Transduction Molecules in Tumor-Infiltrating, Near-Tumor Tissue, and Peripheral Blood Lymphocytes
29. Vascular endothelial growth factor and prognosis in patients with node-negative breast cancer
30. Low-dose temozolomide before dendritic-cell vaccination reduces (specifically) CD4+CD25++Foxp3+ regulatory T-cells in advanced melanoma patients.
31. Vascular endothelial growth factor and prognosis in patients with node-negative breast cancer
32. Role of SIRT-3, p-mTOR and HIF-1α in Hepatocellular Carcinoma Patients Affected by Metabolic Dysfunctions and in Chronic Treatment with Metformin.
33. DC Vaccine Potency Correlates With Efficient Induction of Tumor-specific Immune Responses After Vaccination of Advanced Melanoma Patients: Preliminary Data With an in vitro Functional Assay
34. Role of SIRT-3, p-mTOR and HIF-1α in Hepatocellular Carcinoma Patients Affected by Metabolic Dysfunctions and in Chronic Treatment with Metformin
35. Metformin and insulin impact on clinical outcome in patients with advanced hepatocellular carcinoma receiving sorafenib. Validation study and biological rationale
36. Interplay Between SIRT-3, Metabolism and Its Tumor Suppressor Role in Hepatocellular Carcinoma
37. Low-dose temozolomide before dendritic-cell vaccination reduces (specifically) CD4+CD25++Foxp3+ regulatory T-cells in advanced melanoma patients.
38. Dendritic cell-based vaccine in advanced melanoma: update of clinical outcome.
39. Basic fibroblast growth factor and vascular endothelial growth factor serum levels in breast cancer patients and healthy women: useful as diagnostic tools?
40. p27/kip1 expression in normal epithelium, benign and neoplastic breast lesions.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.